Cevimeline for the Treatment of Postirradiation Xerostomia in Patients With Head and Neck Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 4, 2007, Pages 1102-1109

  Chambers, Mark S ^a   Posner, Marshall ^b   Jones, Christopher Uwe ^c   Biel, Merrill A ^d   Hodge, Kenneth M ^e   Vitti, Robert ^f   Armstrong, Ingrid ^f   Yen, Cindy ^f   Weber, Randal S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Radiological Associates of Sacramento Medical Group Inc   (United States)

^d Ear Nose and Throat Specialty Care of Minnesota   (United States)

^e Commonwealth Ear Nose and Throat ^*  (United States)

^f Daiichi Pharmaceutical Corporation   (United States)

Author keywords

Cevimeline; Dry mouth; Head and neck cancer; Postirradiation xerostomia; Saliva

Indexed keywords

CEVIMELINE; ORAL ADMINISTRATION; POSTIRRADIATION XEROSTOMIA; RESPONSE RATES; SALIVA;

DOSIMETRY; ONCOLOGY; TUMORS;

RADIOTHERAPY;

CEVIMELINE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SALIVATION; SIDE EFFECT; SWEATING; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

DOUBLE-BLIND METHOD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; SALIVATION; THIOPHENES; XEROSTOMIA;

EID: 34447332530     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.019     Document Type: Article

References (25)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Jha N., Seikaly H., Harris J., et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 66 (2003) 283-289
3. Whitmyer C.C., Waskowski J.C., and Iffland H.A. Radiotherapy and oral sequelae: Preventive and management protocols. J Dent Hyg 71 (1977) 23-29
4. Taylor S.E., and Miller E.G. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Proc Soc Exp Biol Med 221 (1999) 14-26
5. Eisbruch A., Kim H.M., Ten Haken R., et al. Dose, volume and function relationships in parotid glands following conformal and intensity modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45 (1999) 577-587
6. Dreizen S., Daly T.E., Drane J.B., et al. Oral complications of cancer radiotherapy. Postgrad Med 61 (1977) 85-92
7. Eisbruch A., Kim H.M., Terrell J.E., et al. Xerostomia and its predictors following parotid-sparing irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 695-704
8. Chambers M.S., Garden A.S., Kies M.S., et al. Post-radiation xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. Head Neck 26 (2004) 796-807
9. Bjordal K., Kaasa S., and Mastekaasa A. Quality of life in patients treated for head and neck cancer: A follow up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 28 (1994) 847-856
10. Harrison L.B., Zelefski M.J., Pfitzer D.G., et al. Detailed quality of life assessments in patients treated with irradiation for cancer of the base of tongue. Head Neck 19 (1997) 169-175
11. Chambers M.S., Garden A.S., Rosenthal D.I., et al. Intensity-modulated radiotherapy: Is xerostomia still prevalent?. Curr Oncol Rep 7 (2005) 131-136
12. Almstahl A., Wikstrom M., Stenberg I., et al. Oral microbiota associated with hyposalivation of different origins. Oral Microbiol Immunol 18 (2003) 1-8
13. Keene H.J., and Fleming T.J. Prevalence of caries-associated microflora after radiotherapy in patients with cancer of the head and neck. Oral Surg Oral Med Oral Pathol 64 (1987) 421-426
14. Rothwell B.R. Prevention and treatment of the orofacial complications of radiotherapy. J Am Dent Assoc 114 (1987) 316-322
15. Ship J.A., and Hu K. Radiotherapy-induced salivary dysfunction. Semin Oncol 31 Suppl. 18 (2004) 29-36
16. MGI Pharma. Salagen (pilocarpine) (2003), MGI Pharma, Bloomington, MN [package insert]
17. Iwabuchi Y., and Masahura T. Sialagogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjögren's syndrome. Gen Pharmacol 25 (1994) 123-129
18. Petrone D., Condemi J.J., Fife R., et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46 (2002) 748-754
19. Daiichi Phamraceutical Corporation. Evoxac (cevimeline) (2005), Daiichi Phamraceutical Corporation, Montvale, NJ [package insert]
20. Iga Y., Arisawa H., Ogane N., et al. (+)-cis-2-methylspiro[1,3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylchooline receptors. Jpn J Pharmacol 78 (1998) 373-380
21. Masunaga H., Ogawa H., Uematsu Y., et al. Long-lasting salivation induced by a novel muscarinic receptor antagonist SNI-2011 in rats and dogs. Eur J Pharmacol 339 (1997) 1-9
22. Johnson J.T., Ferretti G.A., Nethery W.J., et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329 (1993) 390-395
23. Chambers M.S., Keene H.J., Toth B.B., et al. Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 (2005) 180-184
24. Fox P.C., Busch K.A., and Baum B.J. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 115 (1987) 581-584
25. Braam P.M., Terhaard C.H., Roesink J.M., et al. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 975-980